Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
NCT ID: NCT01162967
Last Updated: 2013-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
78 participants
INTERVENTIONAL
2010-09-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Benznidazole
Benznidazole
Standard dosage
Posaconazole, low dose
Posaconazole
Posaconazole, high dose
Posaconazole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Benznidazole
Standard dosage
Posaconazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Vall d'Hebron
OTHER
Tropical Medicine and International Health Unit Drassanes. Barcelona
UNKNOWN
International Health Unit Metropolitana Nord. Santa Coloma.
UNKNOWN
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Molina Israel, MD
Role: PRINCIPAL_INVESTIGATOR
Infectious Disease Department Vall d'Hebron Hospital
Pahisssa Albert, MD Ph
Role: STUDY_CHAIR
Infectious Disease Department Vall d'Hebron Hospital
Gomez Jordi, MD
Role: PRINCIPAL_INVESTIGATOR
International Health Unit Drassanes
Valerio Lluis, MD
Role: PRINCIPAL_INVESTIGATOR
International Health Unit Metropolitana Nord
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
International Health Unit Metropolitana Nord
Santa Coloma, Barcelona, Spain
Infectious Disease Department Vall d'Hebron Hospital
Barcelona, , Spain
International Health Unit Drassanes
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Molina I, Gomez i Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sanchez-Montalva A, Vidal X, Pahissa A. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med. 2014 May 15;370(20):1899-908. doi: 10.1056/NEJMoa1313122.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHAGASAZOL01
Identifier Type: -
Identifier Source: org_study_id